- Who We Are and What We Do
- Research Projects
- HIV Vaccine Trials Unit (HVTU)
- Penn Center for AIDS Research (CFAR)
- Risk Assessment Battery (RAB)
- Community Advisory Board
- Contact Us
- Support Our Work
- Follow Us on Twitter
David Metzger, PhD
Research Associate Professor
Director of the HIV/AIDS Prevention Research Division
Department of Psychiatry bio page
David Metzger, Ph.D. is Research Associate Professor and Director of the HIV/AIDS Prevention Research Division at the University of Pennsylvania, Department of Psychiatry. He is also the Principal Investigator for the NIAID funded HIV Prevention Clinical Trials Unit in Philadelphia and the Director of the Social and Behavioral Sciences Core of the Penn Center for AIDS Research (CFAR).
Since 1989, he and colleagues from the Center for Studies of Addiction have been conducting HIV-related longitudinal studies of injection and non-injection drug users. Under his direction, over 3,000 drug using subjects from Philadelphia have been enrolled in HIV studies known collectively as the Risk Assessment Projects (RAP). Dr. Metzger’s research division has developed innovative community-based strategies for recruiting and retaining individuals at high risk of HIV infection into longitudinal studies of HIV prevention interventions. A primary objective of this work has been to provide valid and reliable data that can increase understanding of the public health impact of participation in substance abuse treatment. Currently, his work involves testing the safety and efficacy of behavioral and biomedical prevention interventions including preventive HIV vaccines, vaginal microbicides, social network interventions, and agonist drug treatment strategies in Philadelphia, Thailand and China.
As chair of the NIH HIV Prevention Trials Network (HPTN) Substance Use Working Group for over six years, he helped design and lead the implementation of two large trials with sites in the United States, and Asia. He has served on the selection committee for the NIDA funded Humphrey Fellowship program and has hosted NIDA funded Invest fellows. He is currently Protocol Chair for the first randomized trial of drug treatment as HIV prevention (HPTN 058), being conducted among 1,500 heroin dependent injectors in Thailand and China. In June of 2007, he was the recipient of the NIDA International Program’s annual award for leadership in international research. In 2008, he was named a guest professor of the Wuhan Center for Disease Prevention and Control, in Wuhan, China.
Back to Top